Immune Globulin (generic), Gammagard News

PHIL HOSSACK / WINNIPEG FREE PRESS archives John Langstaff: i 1 2We doni 1 2t think we need to worry about life after bio-defence.i 1 2 WINNIPEG-BASED Cangene doubled its profits and generated record sales in the worst economy in memory and says it believes there is still plenty of growth left in its lucrative bio-defence work.

The University of Massachusetts Medical School says it's taking part in testing a human monoclonal antibody developed to neutralize the rabies virus.

Washington, Oct 1 : A clinical trial testing the safety and activity of a human monoclonal antibody developed to neutralize the rabies virus has been launched in King Edward Memorial Hospital in Mumbai, India.

Author affiliations: Baxter Bioscience, Vienna, Austria ; and US Food and Drug Administration, Bethesda, Maryland, USA Abstract This study investigated the association of ongoing West Nile virus infections with neutralizing antibody titers in US plasma-derived intravenous immune globulin released during 20032008.

FDA on September 17 approved the marketing of Gammaplex, a ready-to-use 5% intravenous immune globulin product for the treatment of primary humoral immunodeficiency.

Australian researchers may have uncovered a clue as to why some people who catch swine flu suffer life-threatening illness.

As many as 3 million Americans may now be immune to the West Nile virus thanks to antibodies they produced after being infected by the bite of an infected mosquito.

Talecris Biotherapeutics updated its initial public offering registration documents with the SEC last week, generating rumors that it might be the first biotech to test the IPO waters .

A programme to produce a "last defence" against swine flu will begin next month, when 800 recovered patients will be asked to give blood from which antibodies will be recovered for use in serum therapy.

Talecris Biotherapeutics updated its initial public offering registration documents with the SEC last week, generating rumors that it might be the first biotech to test the IPO waters .

Cangene Corporation today announces that it has withdrawn its Marketing Authorization Applications with respect to WinRho SDF Immune Globulin for Injection) that were underway in 16 European Union countries and it will also cease marketing the product in the EU countries where Marketing Authorizations had already been obtained.

Cangene Corporation today announces that it has withdrawn its Marketing Authorization Applications with respect to WinRho SDF Immune Globulin for Injection) that were underway in 16 European Union countries and it will also cease marketing the product in the EU countries where Marketing Authorizations had already been obtained.

Octapharma USA is now accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine.

Illinois Department of Public Health Director Damon T. Arnold on Monday announced the activation of the Illinois Public Health Mutual Aid System to assist the Rock Island County Health Department with a vaccination clinic in response to a hepatitis A outbreak.

Officials are urging thousands of people who ate at a McDonald's restaurant in northwestern Illinois to get either hepatitis A vaccine or immune globulin immediately.

WALTHAM,A Mass. The Alzheimera s disease market will grow by 11% a year, thanks in part to new therapies for treating the disease, according to a report by market research firm Decision Resources.

AUSTRALIANS are being urged to have rabies vaccinations before heading to Bali amid fears the island will exhaust supplies of the treatment for people bitten by rabid animals.

Following the Federal Trade Commission's filing of a lawsuit to block the transaction, CSL Limited announced on June 8, 2009, that it will not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics.

Australian biotech CSL Ltd. and Talecris Biotherapeutics Inc. decided to abandon their $3.1 billion merger agreement rather than fight the Federal Trade Commission, which filed a suit to block the deal.

Privately held Talecris Biotherapeutics remains committed to the $3.1 billion acquisition in which it would become part of Australia-based CSL, the company's top executive said Thursday.